NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,813.30+₹52.30 (+2.97%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
Loading market information…
NSE · KOPRAN.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:18 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Kopran Limited’s quoted price sits in the upper half of its reported 52-week range, 17.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kopran Limited’s forward annual dividend is ₹3.00 per share, paid annual. The forward yield is 1.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kopran Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a diverse array of dosage formats, such as tablets, capsules, dry powders, suspensions, and injectable solutions. The company's active pharmaceutical ingredients cater to a broad spectrum of therapeutic applications, encompassing macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, antihistamines, anti-acne treatments, anti-infectives, urologicals, anti-thrombotics, antidiabetics, pain management, gastroenterology, and cardiovascular medications. Established in 1958, Kopran Limited maintains its corporate headquarters in Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:20 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
₹1,813.30+₹52.30 (+2.97%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
₹3,576.90-₹104.05 (-2.83%)
Kwality Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 7.49% below the high.
₹957.10+₹10.60 (+1.12%)
Sakar Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 22.22% below the high.
₹2,593.30-₹19.50 (-0.75%)
NGL Fine-Chem Limited’s quoted price sits in the upper half of its reported 52-week range, 28.0% below the high.
₹426.70-₹13.05 (-2.97%)
Fermenta Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.8% below the high.
₹87.69+₹7.95 (+9.97%)
Anuh Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 11.87% below the high.
₹206.00-₹3.14 (-1.5%)
Kilitch Drugs (India) Limited’s quoted price sits in the upper half of its reported 52-week range, 23.11% below the high.
₹184.00+₹2.07 (+1.14%)
Wanbury Limited’s quoted price sits in the lower half of its reported 52-week range, 48.57% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
